Y 134 is a SERM displaying selectivity for ERα over ERβ.
ChEBI: [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(4-propan-2-yl-1-piperazinyl)phenyl]methanone is an aromatic ketone.
Selective estrogen receptor modulator (SERM) that displays selectivity for ER α over ER β (K i values are 0.09 and 11.31 nM respectively) and no cross-reactivity with mineralocorticoid, glucocorticoid, androgen and progesterone receptors. Acts as an agonist in the bone and antagonist in reproductive tissue. Suppresses estrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells.
Y134 (1-3 mg/kg/day; p.o. for 3 days) abolishes the E2-induced mammary gland terminal end bud (TEB) outgrowth in ovariectomized rats. Y134 inhibits uterine cell proliferation induced by E2 in a dose-dependent manner[1].
| Animal Model: | Four-week old female Sprague-Dawley rats were received ovariectomy[1] |
| Dosage: | 1, 3 mg/kg |
| Administration: | P.o. daily for 3 days |
| Result: | Abolished the effect exerted by E2 in a dose-dependent manner.
|
ERα: 0.09 nM (Ki); ERβ: 11.31 nM (Ki)